Democrats seek to boost FDA authority over compounders in wake of meningitis outbreak
This article was originally published in Scrip
As the Centers for Disease Control and Prevention (CDC) on 9 October upped the number of US deaths to 11 related to the fungal meningitis outbreak linked to a tainted steroid compounded in Massachusetts – revealing New Jersey joined nine other states where 119 cases of the infection have now been reported – two Democrats said they planned to introduce separate pieces of legislation aimed at closing the gaps in regulating compounding pharmacies, especially those making injectable drugs.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.